VetDC/CSU Partnership Highlighted in Article on Research Spending

canine lymphoma treatment

TANOVEA®-CA1 (rabacfosadine for injection), a novel treatment for lymphoma in dogs, is the result of a powerful collaboration involving VetDC, veterinarians nationwide, and the families that allow us to care for their dogs with lymphoma. VetDC was originally founded out of CSU Ventures – the University of Colorado’s technology transfer office – to leverage the impressive research coming out of CSU’s top ranked Flint Animal Cancer Center in order to develop novel cancer drugs for companion animals.

A new InnovatioNews article provides details on CSU’s culture of innovation and research spending that reached $338.4 million in fiscal year 2017. While national support for research has declined, CSU remains committed to being what Alan Rudolph, CSU’s VP for research, has called “an objective source of discovery and translation of science.” It’s continuing partnership with VetDC is a prime example.

Find Help for Your Pet

Learn more about TANOVEA-CA1 canine lymphoma treatment and find a canine lymphoma veterinary specialist in your area at our website: A veterinary oncologist can help you determine the best treatment plan for you and your pet.